Across TCGA pan-cancer cohorts, AMZ2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AMZ2 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AMZ2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMZ2 expression acts as an unfavorable survival marker.

BLCA are the cancer types where AMZ2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.090	0.469	.009	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: AMZ2 tumor-vs-normal RNA expression · all AMZ2 data types